Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Cortés J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Chiu JWY, Pedrini JL, Li W, Yonemori K, Bianchini G, Loi S, Borges GS, Wang X, Bachelot T, Nakatani S, Ashfaque S, Liang Z, Egorov A, Hamilton E.
Cortés J, et al. Among authors: liang z.
Nat Med. 2024 Jun 2. doi: 10.1038/s41591-024-03021-7. Online ahead of print.
Nat Med. 2024.
PMID: 38825627